Fig. 2From: (1,3)-β-d-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized triala Kaplan-Meier plots showing the evolution with time of the percentage of patients who remained on antifungals in the (1,3)-β-d-glucan and control groups. b Probability of survival from study inclusion (day 0) through day 30 for patients in the (1,3)-β-d-glucan and control groupsBack to article page